Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.02.

EBIT: As of FY2026 Q1, the actual value is USD -1.872 M.

Bioxytran, Inc. operates as a single segment and has not yet generated significant revenues from its pharmaceutical products, remaining in the research and development phase as of March 31, 2026.

Operational Metrics

• Net Loss: The company reported a net loss of - $2,068,989 for the three months ended March 31, 2026, an increase from - $1,353,635 for the same period in 2025, primarily due to a $1,278,600 bonus award to the CEO in January 2026.
• Total Operating Expenses: Total operating expenses for the three months ended March 31, 2026, were $1,933,053, up from $515,142 in the prior year period.
• Research and Development (R&D) Expenses: R&D expenses decreased to $225,479 for the three months ended March 31, 2026, compared to $349,500 for the same period in 2025. This includes $3,000 for process development, $225 for product development, $216,254 for regulatory, $0 for clinical trials, and $6,000 for project management.
• General and Administrative (G&A) Expenses: G&A expenses significantly increased to $1,707,574 for the three months ended March 31, 2026, from $165,642 in the corresponding 2025 period. Key components include $262,567 for payroll and related expenses, $51,588 for legal, accounting, and other professional services, $36,000 for marketing expense, $67,404 for miscellaneous G&A expenses, $1,278,600 for compensation expense to BoD and Management, and $11,415 for compensation expense to consultants.
• Other Expenses: Total other expenses were $135,936 for the three months ended March 31, 2026, a decrease from $838,493 in the same period of 2025. This includes a change in fair value of derivative of $73,136, interest expense of $35,729, interest expense affiliate of $24,963, and amortization of Intellectual Property of $2,108.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities was - $238,610 for the three months ended March 31, 2026, compared to - $167,323 for the same period in 2025.
• Net Cash Used in Investing Activities: Net cash used in investing activities was - $9,227 for the three months ended March 31, 2026, primarily for filing a patent, compared to - $15 in 2025.
• Net Cash Provided by Financing Activities: Net cash provided by financing activities totaled $200,970 for the three months ended March 31, 2026, including $145,701 from stock sales and $95,339 from warrant sales, partially offset by - $40,070 in short-term loans from affiliates. This compares to $166,532 provided by financing activities in 2025, primarily from affiliate loans.
• Cash, End of Period: Cash on hand at March 31, 2026, was $463,047, a decrease from $509,914 at the beginning of the period.

Unique Metrics

• Accumulated Deficit: The accumulated deficit increased to - $23,113,235 at March 31, 2026, from - $21,044,246 at December 31, 2025.
• Net Working Capital: Net working capital was - $4,547,075 at March 31, 2026, worsening from - $2,736,429 at December 31, 2025.
• Current Assets: Total current assets were $463,047 at March 31, 2026, down from $513,465 at December 31, 2025.
• Current Liabilities: Total current liabilities increased to $5,010,121 at March 31, 2026, from $3,249,894 at December 31, 2025. This includes accounts payable and accrued expenses of $1,065,504, accounts payable affiliates of $869,237, un-issued shares liability of $27,687, un-issued shares liability affiliates of $1,360,606, loan from affiliates of $355,598, other short-term loans of $50,000, derivative liability of $476,489, and convertible notes payable of $805,000.
• Convertible Notes Payable: The principal amount of convertible notes payable remained at $805,000 at March 31, 2026, with accrued interest of $313,685. The 2021 Note has been in default since March 1, 2025, incurring an 18% default interest rate.
• Derivative Liability: The derivative liability was $476,489 at March 31, 2026, compared to $403,353 at December 31, 2025.
• Stock-based compensation expense: Stock-based compensation expense totaled $1,290,015 for the three months ended March 31, 2026, with $1,278,600 attributed to affiliates.

Future Outlook and Strategy

Bioxytran, Inc. anticipates needing to raise approximately $2-3 million in 2026 to fund operations and continue product development for the next 15 months. The company plans to pursue additional capital through private placements and/or public offerings of debt and/or equity securities. Without sufficient additional funding or strategic partnerships, Bioxytran, Inc. may be forced to curtail or cease operations.